VIVEVE MEDICAL, INC. (NASDAQ:VIVE) Files An 8-K Other Events

VIVEVE MEDICAL, INC. (NASDAQ:VIVE) Files An 8-K Other Events
Item 9.01. Other Events.

Story continues below

Stress Urinary Incontinence Feasibility Study Results

On December 6, 2018, Viveve Medical, Inc. (the “Company”) issued a press release titled “Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study.” A copy of this press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.

Business Update

On December 6, 2018, the Company filed with the Securities and Exchange Commission (the “SEC”) a preliminary prospectus supplement in connection with a proposed public offering of shares of the Company’s common stock (the “Offering”). The preliminary prospectus supplement contains an updated description of certain aspects of the Company’s business. Accordingly, the Company is filing this information with this Current Report on Form 8-K for the purpose of updating the description of certain aspects of its business from the disclosure contained in the Company’s prior filings with the SEC, including the Company’s most recent Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018. The updated disclosure is filed herewith as Exhibit 99.2 and is incorporated herein by reference.

Launch of Public Offering of Common Stock

On December 6, 2018, the Company issued a press release announcing the Offering. A copy of this press release is filed herewith as Exhibit 99.3 and is incorporated herein by reference.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits


VIVEVE MEDICAL, INC. Exhibit
EX-99.1 2 ex_131293.htm EXHIBIT 99.1 ex_131293.htm Exhibit 99.1   Viveve Announces Positive 12-Month Data from Stress Urinary Incontinence Feasibility Study   –     72% of women treated experienced an improvement in the one-hour pad weight with an overall mean improvement of 56%   –     Clinically meaningful benefit achieved at one year across all patient-reported outcome measures   –     Complete results to be presented during live webcast of SUI symposium with physician key opinion leaders on December 11,…
To view the full exhibit click here

About VIVEVE MEDICAL, INC. (NASDAQ:VIVE)

Viveve Medical, Inc., formerly PLC Systems, Inc., designs, develops, manufactures and markets medical devices for the non-invasive treatment of vaginal laxity. The Company’s Viveve Treatment is a non-invasive solution for vaginal laxity that is performed in approximately 30 minutes, in a physician’s office. The Viveve System uses monopolar radiofrequency (RF) energy to generate low temperature heat. The vaginal mucosa is simultaneously cooled while this non-ablative heat is delivered into the submucosal layer. The RF energy stimulates the formation of collagen and causes the collagen fibers to remodel thereby tightening the submucosal tissue of the vaginal introitus. The RF stimulation causes subtle alterations in the collagen that can renew the tissue and further tighten the vaginal tissue over the next 1 to 3 months following treatment (the Viveve Treatment) and lead to increased sexual function.

An ad to help with our costs